Global Cardiovascular Disease Market to 2022: Market Set to Grow Very Slowly to $146.4 Billion by 2022 with Sanofi & Novartis Becoming Market Leaders

Dublin, Dec. 15, 2016 -- Research and Markets has announced the addition of the "Global Cardiovascular Disease Market to 2022 - Sanofi and Novartis to Become Market Leaders as Praluent and Entresto Drive Revenue Growth" report to their offering.

Cardiovascular disease (CVD) covers a range of difference diseases and conditions affecting the heart and/or blood vessels. The most crucial risk factors for CVD are hypertension and dyslipidemia of which accelerate the development of atherosclerotic plaques building up within blood vessels. As atheroma develops its causes stenosis of the blood vessels which can restrict blood flow to the body, brain or heart depending on its locale. It is also possible for the fibrous cap of the plaque to break off, triggering the coagulation cascade and causing a thrombus to form locally which can completely occlude blood flow.

There has been vast scientific innovation within the CVD therapeutics market over recent decades, particularly within the anti-dyslipidemia market with the advent of statins such as Lipitor, the best-selling drug of all time, which produce marked reductions in cholesterol levels. More recently, the commonly used direct factor Xa inhibitors which produce anti-coagulant effects, have been made available for oral administration and the advent of PCSK9 inhibitors provide a viable alternative dyslipidemia treatment for when statins are unsuitable or inefficient. There are currently 1368 pipeline drugs within the cardiovascular disease market, the largest therapy area being thrombosis, with 406 pipeline products indicated for treatment or prevention of thrombotic events.

Among those pipeline drugs expected for imminent release to market there is a mixture of first-in-class products, typically anti-dyslipidemia drugs aiming to provide alternatives to statin therapy, and drugs belonging to currently popular classes such as the aforementioned PCSK9 inhibitors and direct factor Xa inhibitors.

Key Topics Covered:

1. Tables & Figures

2 Introduction
2.1 Therapy Area Introduction
2.2 Symptoms
2.3 Etiology, Pathophysiology, Comorbidities and Complications
2.3.1 Hypertension
2.3.2 Dyslipidemia
2.3.3 Thrombotic events
2.4 Diagnosis
2.4.1 Hypertension
2.4.2 Dyslipidemia
2.4.3 Thrombotic events
2.5 Prognosis
2.6 Epidemiology Patterns and Forecasts - Prevalence and Patient Segmentation
2.6.1 Hypertension
2.6.2 Dyslipidemia
2.6.3 Thrombotic events
2.7 Treatment
2.7.1 Thiazide Diuretics
2.7.2 Angiotensin Converting Enzyme Inhibitors
2.7.3 Angiotensin Receptor Blockers
2.7.4 Calcium Channel Blockers
2.7.5 Statins
2.7.6 Anticoagulants
2.7.7 Antiplatelet Drugs
2.7.8 Beta-adrenoceptor antagonists (Beta blockers)
2.7.9 Other Drugs

3 Key Marketed Products
3.1 Overview
3.2 Crestor (rosuvastatin) - AstraZeneca
3.3 Zetia (ezetimibe) - Merck & Co
3.4 Lipitor (atorvastatin) - Pfizer
3.5 Praluent (alirocumab) - Sanofi
3.6 Xarelto (rivaroxaban) - Bayer
3.7 Eliquis (apixaban) - Bristol-Myers Squibb and Pfizer
3.8 Plavix (clopidogrel) - Sanofi
3.9 Brilinta (ticagrelor) - AstraZeneca
3.10 Entresto (valsartan plus sacubitril) - Novartis
3.11 Benicar (olmesartan medoxomil) - Daiichi Sankyo
3.12 Conclusion

4 Pipeline Landscape Assessment
4.1 Overview
4.2 Pipeline Development Landscape
4.3 Molecular Targets in the Pipeline
4.4 Clinical Trials
4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target
4.5 Conclusion

5 Multi-Scenario Market Forecast to 2022
5.1 Overall Market Size
5.2 Generic Penetration
5.3 Revenue Forecast by Molecular Target
5.3.1 Coagulation Cascade
5.3.2 P2Y12 Receptors
5.3.3 Beta 1 Adrenergic Receptors
5.3.4 PCSK9 Inhibitors
5.3.5 HMG-CoA Reductase Inhibitors (statins)
5.3.6 Renin angiotensin system (RAS)
5.3.7 Revenue and Market Share Analysis by Company
5.3.8 Assessment of Key Pipeline Products

6 Company Analysis and Positioning
6.1 Company Landscape
6.2 Marketed and Pipeline Portfolio Analysis

7 Strategic Consolidations
7.1 Licensing Deals
7.1.1 Deals by Region, Year and Value
7.1.2 Deals by Stage of Development and Value
7.1.3 Deals by Molecule Type, Mechanism of Action and Value
7.1.4 Licensing Deals Valued Above $200m
7.2 Co-development Deals
7.2.1 Deals by Region, Year and Value
7.2.2 Deals by Stage of Development and Value
7.2.3 Deals by Molecule Type, Mechanism of Action and Value
7.2.4 Co-development Deals Valued Above $100m

8 Appendix

For more information about this report visit http://www.researchandmarkets.com/research/cc55nt/global

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716
         Related Topics: Cardiovascular Drugs